Physician profile
Sandra L Abbott
NPI 1871764837
$5,693.29
in general payments reported to CMS, 2019-2025
29 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $620 · 2022: $792 · 2023: $1,055 · 2024: $1,975 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,281.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,542.66 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $1,036.21 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $510.71 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Abbvie INC. | $479.51 | 2022-2025 | Synthroid |
| Amgen INC. | $377.15 | 2021-2025 | Prolia, Evenity, Prolia |
| Lilly USA, LLC | $337.50 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $225.98 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.11 | 2021-2025 | Jardiance |
| Beta Bionics, INC. | $140.92 | 2024 | Ilet Bionic Pancreas |
| Corcept Therapeutics | $135.88 | 2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $117.40 | 2024-2025 | |
| Amarin Pharma, INC. | $67.81 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $50.79 | 2021-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $47.55 | 2021 | |
| Ibsa Pharma INC. | $43.44 | 2022-2024 | Tirosint, Licart |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $41.29 | 2022-2023 | Gvoke Hypopen |
| Cequr Corporation | $36.79 | 2022-2023 | Cequr Simplicity |
| Radius Health, INC. | $36.65 | 2024-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $33.87 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $31.01 | 2024-2025 | Unithroid |
| Sequel Med Tech, LLC | $29.12 | 2025 | Twiist |
| Insulet Corporation | $25.22 | 2025 | Omnipod |
| Horizon Therapeutics Plc | $23.76 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $21.14 | 2023 | |
| Clarus Therapeutics INC. | $19.86 | 2021 | |
| Recordati_rare_diseases_inc. | $18.68 | 2025 | Isturisa |
| Almatica Pharma LLC | $16.23 | 2025 | Teriparatide |
| Merck Sharp & Dohme LLC | $16.07 | 2021 | |
| Esperion Therapeutics, INC. | $14.98 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.